Neuroone Med Technologies Corp Stock Price, News & Analysis

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) published its 2022 Annual Letter to Shareholders, highlighting accomplishments from fiscal year 2021 and outlining goals for 2022 and beyond. Significant achievements include a $12.5M equity raise, uplisting to Nasdaq, and successful feasibility testing of their electrode technology. Looking ahead, the company plans to resubmit for FDA approval of its sEEG product line and continue developing its ablation system and electrode technologies for chronic conditions like epilepsy and Parkinson's disease.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will present its innovative technology at the H.C. Wainwright Global Investment Conference from May 23-26, 2022 in Miami. The presentation is scheduled for May 25, 2022, at 3:30 PM ET, and will be available via webcast. CEO Dave Rosa will highlight progress in minimally invasive, high-precision solutions for neurological conditions. NeuroOne aims to reduce costs and improve patient outcomes using advanced electrode technologies. For more information, visit n1mtc.com.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announces the FDA's recent decision to uphold its denial of the Evo® sEEG Electrode for extended use beyond 24 hours. Although the FDA encourages the company to submit new evidence to support a substantial equivalence claim, the timeline for resubmission is set for August 2022. The CEO expressed disappointment but remains optimistic about demonstrating compliance through ongoing testing. NeuroOne is also exploring marketing opportunities for intraoperative use through Zimmer Biomet.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its second quarter fiscal 2022 results, reporting product revenue of $37,000, up from $18,000 in Q2 2021. The company faced delays in collaboration revenue due to FDA decisions, totaling $20,000 last year. Operating expenses rose to $3.0 million, with a net loss of $3.1 million, compared to $2.4 million the previous year. As of March 31, 2022, cash reserves decreased to $12.9 million. The company provided updates on its product development, including ongoing FDA appeals and new manufacturing qualifications.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced that it will hold a conference call on May 12, 2022, at 4:30 PM Eastern Time to discuss its financial results for the second quarter of fiscal 2022, which ended on March 31, 2022. The company specializes in developing minimally invasive solutions for neurological disorders such as epilepsy and Parkinson's disease. NeuroOne's technology aims to improve patient outcomes while potentially lowering hospitalizations and costs.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will present at NobleCon18 from April 19-21, 2022. CEO Dave Rosa will discuss advancements in minimally invasive technologies aimed at treating neurological disorders such as epilepsy and Parkinson's disease. The presentation is scheduled for April 21 at 11:30 a.m. ET, with breakout sessions on April 20 and 21. The event will take place at the Hard Rock Hotel & Casino in Hollywood, Florida. The company is also exploring applications of its technology in artificial intelligence.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced a telephone replay of its investor conference call will be available until April 11, 2022. The call discussed the company's recent disclosures, including clarification on its 510(k) clearance request for the Evo® sEEG Electrode for short-term use. CEO Dave Rosa, along with biocompatibility expert Dr. William Wustenberg, addressed public questions during the call. The device is already cleared for use of less than 24 hours. For further details, visit www.n1mtc.com.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on March 29, 2022, at 10:00 am ET, to discuss recent disclosures related to its 510(k) clearance request for the Evo® sEEG Electrode. This device is already cleared for temporary use of less than 24 hours and seeks approval for less than 30 days. Investors and interested parties can join via the provided dial-in numbers or access the live webcast. The call aims to clarify the recent 8-K filing and answer participant questions.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced the approval of an equity award as part of its 2021 Inducement Plan, effective March 1, 2022. This award was granted to a new employee, providing them the option to purchase 10,000 shares at $1.95 per share, the closing price on the granting date. The award will vest 25% after one year and the rest in monthly installments over three years, contingent on continued employment. This move aligns with Nasdaq's regulations requiring public disclosure of non-stockholder approved equity awards.